Physician profile
Andre L Smith
NPI 1801980636
$1,373.83
in general payments reported to CMS, 2019-2025
13 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $37.58 · 2022: $123 · 2023: $32.60 · 2024: $237 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.32 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $313.13 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.82 | 2019-2022 | |
| Genzyme Corporation | $167.54 | 2025 | |
| United Therapeutics Corporation | $147.82 | 2024 | Tyvaso |
| Inspire Medical Systems, INC. | $115.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $109.25 | 2019 | |
| Genentech USA, INC. | $99.99 | 2019 | |
| Insmed, INC. | $38.42 | 2020-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $26.31 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $20.24 | 2024 | Airsupra |
| Inogen, INC. | $19.39 | 2025 | |
| Advanced Respiratory, INC | $17.86 | 2019 | |
| Merck Sharp & Dohme LLC | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.